Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Takiguchi

Showing results (151-160 of 151) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 151 results.
ESMO Open|July 17, 2022
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancerK Hotta, T Hida, H Nokihara, et al.
Pageof 16

Showing results (151-160 of 151) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 151 results.
ESMO Open|July 17, 2022
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancerK Hotta, T Hida, H Nokihara, et al.
Pageof 16